The earnings call presented a mixed outlook. While there were significant positive developments like the expansion of CPT codes and increased device placements, the company faced substantial challenges, including revenue declines and international market disruptions. Despite efforts to expand the market and improve reimbursement rates, financial performance was impacted by legal expenses and decreased international and equipment revenues.

Company Guidance -

Q3 2025

During the STRATA Skin Sciences Inc. Second Quarter 2025 Financial Results and Corporate Update Conference Call, significant guidance was provided, highlighting several key metrics and strategic initiatives. The company reported total revenue of $7.7 million for Q2 2025, representing a 9% decline compared to Q2 2024, primarily due to international market challenges. Despite removing 21 XTRAC laser devices from suboptimal partners, STRATA placed 19 new devices with promising new accounts, marking the highest U.S. placements in six quarters. The company generated approximately 1,100 direct-to-consumer-driven patient appointments with a 61% show rate, and their RDX system processed benefits for about 5,100 patients. Additionally, STRATA's efforts to expand reimbursement eligibility for their excimer laser treatments are expected to significantly increase their addressable market, potentially tripling their patient population and increasing revenue per patient. The company is also pursuing an increase in reimbursement rates through economic data submissions and is focused on optimizing clinic partnerships and launching innovative direct-to-consumer campaigns. Furthermore, STRATA's ongoing litigation against LaserOptek is positioned to potentially recover significant damages, reflecting the company's proactive legal strategy.

Expansion of CPT Codes

The American Medical Association CPT Editorial Panel expanded CPT codes for STRATA's XTRAC 308-nanometer excimer laser, enabling coverage for multiple inflammatory and autoimmune skin conditions, potentially tripling the addressable market to 30 million patients.

Increased Device Placements

STRATA placed 19 new XTRAC devices with accounts interested in growth, marking the highest number of placements in the U.S. in the last six quarters.

Market Expansion Potential

The company is preparing to expand into new indications with the potential for higher reimbursement rates, supported by submitted economic data. This could lead to increased revenue per patient procedure.

Positive Direct-to-Consumer Campaigns

Generated 1,100 DTC-driven patient appointments with a 61% show rate and handled benefits for approximately 5,100 patients, demonstrating strong demand for excimer laser therapy.

TheraClearX Growth

Installed base of TheraClearX devices grew to 161 in the U.S., up from 117 in Q2 2024, indicating a growing portion of the company's revenue.

Strata Skin Sciences (SSKN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SSKN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.39 / -	-0.192	―	―	―
Aug 13, 2025	2025 (Q2)	-0.29 / -0.19	0.533	-134.90% (-0.72)	―
May 14, 2025	2025 (Q1)	-0.52 / -0.23	-0.432	47.22% (+0.20)	―
Mar 27, 2025	2024 (Q4)	-0.30 / -0.86	-0.416	-107.93% (-0.45)	―
Nov 13, 2024	2024 (Q3)	-0.45 / -0.19	0.397	-148.36% (-0.59)	―
Aug 14, 2024	2024 (Q2)	-0.70 / 0.53	-0.025	2232.00% (+0.56)	―
May 15, 2024	2024 (Q1)	-0.65 / -0.43	-0.205	-110.73% (-0.23)	―
Mar 27, 2024	2023 (Q4)	-0.20 / -0.42	0.45	-192.44% (-0.87)	―
Nov 14, 2023	2023 (Q3)	-0.40 / 0.40	-0.3	232.33% (+0.70)	―
Aug 09, 2023	2023 (Q2)	-0.55 / -0.03	-0.468	94.66% (+0.44)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SSKN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$1.88	$1.81	-3.72%
May 14, 2025	$2.64	$2.68	+1.52%
Mar 27, 2025	$2.71	$2.69	-0.74%
Nov 13, 2024	$3.35	$3.10	-7.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Strata Skin Sciences Inc (SSKN) report earnings?

Strata Skin Sciences Inc (SSKN) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Strata Skin Sciences Inc (SSKN) earnings time?

Strata Skin Sciences Inc (SSKN) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SSKN EPS forecast?

SSKN EPS forecast for the fiscal quarter 2025 (Q3) is -0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing